Hello, ladies and gentlemen, thank you for standing by for Zepp Health Corporation Second Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. Today's conference call is being recorded. I would now like to turn the call over to your host Ms. Grace Zhang, Director of Investor Relations for the company. Please go ahead, Grace.

Hello, everyone, and welcome to Zepp Health Corporation's second quarter earnings conference call. The company's financial and operating results were issued in our press release via Newswire services earlier today and are posted online. You can also view the earnings press release and the slides, to which we will refer on this call, by visiting the IR section of the company's website at ir.zepp.com. Participating in today's call are Mr. Huang Wang, our Chairman of the Board of Directors and Chief Executive Officer; and Mr. Leon Deng, our Chief Financial Officer. The company's management will begin with prepared remarks and the call will conclude with a Q&A session. Mr. Mike Yeung, our Chief Operating Officer will join us for Q&A session. Before we continue, please note that today's discussion will contain forward-looking statements made under the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties. As such, the company's actual results may be materially different from the views expressed today. [Technical Difficulty] and other risks and uncertainties is included in the company's Annual Report on 20-F for the fiscal year ended December 31, 2020, and other filings as filed with the US Securities and Exchange Commission. The company does not assume any obligation to update any forward-looking statements, except required under applicable law. Please also note that Zepp's earnings press release and this conference call include discussions of unaudited GAAP financial information, as well as unaudited non-GAAP financial information. Zepp's press release contains a reconciliation of the unaudited non-GAAP measures to the unaudited most directly comparable GAAP measures. I'll now turn the call to our CEO Mr. Huang Wang.

Hello, everyone. Thank you for joining our call. Second quarter results demonstrated strong continued progress on Zepp Health's mission of connecting health with technology and in our strategic plan to build a company driven predominantly by its own brands and powered by our own proprietary technology. Let me highlight some key examples from the quarter. In the second quarter, we modestly topped our guidance range. Our own Amazfit and Zepp-branded product revenue continued to grow at 81% versus last year same period. In June, in the IDC Worldwide Quarterly Wearable Device Tracker, Zepp Health's self-branded Amazfit and Zepp watches were recognized as being among the leading shippers of other smartwatches in the first quarter of this year. This is a tremendous proof point for the progress of our own brand. It is my strong conviction that the key to that success are our proprietary smart device technology, a faster pace of innovation and a broadening line of products and future sets and price points that are attractive to many different customers around the world. We have not gotten to this point by being a me-too company, assembling devices with our special parts. I know that, being a relentless technology leader is the key path to success. Two weeks after the end of the quarter in July, we held our Annual Developer’s Conference, Next Beat 2021. I view this as the most important event of the year. As we demonstrate and discuss our new proprietary technology and discuss future courses of development, it also serves as a key engineering recruiting event. This year, we announced the next generation of our proprietary smart device AI chip, the Huangshan 2S, which offers substantial performance increases such as reducing operating power consumption by 56%, reducing normal power consumption by 93% and improving -- improvement…

Thank you, Huang. As I did last quarter, I want to focus on highlighting what I think are the handful of the most important metrics. Starting with sales, we're especially with the continuing growth of our own Amazfit and Zepp-branded products globally. The pandemic slowed that growth in 2020 but the year-over-year results for the first two quarters of 2021, showed year-over-year growth rates of 84% and 81% in the last two quarters for self-branded products. As Huang noted, the best is yet to come this year with new products and functionality that we believe will continue to drive our growth in this side of our business. The launch of the Mi Band 6 in the quarter provided strong growth in our Xiaomi product sales, as well as we are working with Xiaomi on the exciting next-generation products as we speak. In fairness, I do also want to point out the timing impact of the launch of the new Xiaomi Mi Band 6 in the second quarter this year instead of the third quarter, which it did last year. Xiaomi sales fluctuations over the quarters create some fluctuations in the company's overall sales and that to some extent overshadows the self-branded product sales performance, which also affects our guidance for the third quarter. Overall, the trend we are seeing speaks to our long-term strategy to grow our self-branded products faster and shift the balance to our own products lessening the reliance on products developed for others. On the pandemic, resignations and lifting of the COVID restrictions in some markets helped our second quarter. How the effects of the Delta and other variants will play out globally in the second half of this year is still very uncertain and that reflects in our guidance as well. Product trends, we discussed on…

We will now begin the question-and-answer session. [Operator Instructions] And the first question today comes from Clive Cheung with Credit Suisse. Please go ahead.

Hi. Good evening, management, and congratulations on the strong second quarter results. My first question is on the guidance. I think this came a little bit lower than expectation. I guess, Leon already outlined some of the key reasons, but could you elaborate more on the second half plans in terms of products, because it is always, I guess, my expectation that the product launches are more second half heavy. And how does that play out now versus, I guess, macro conditions? My second question is on the investment income. I guess, there is 13 million on investment income and then 24 on equity method investments. Could you give us the background of these and then how we should expect these going forward, particularly in the second half of 2021? Thank you.

Hi, Clive. Thank you for your questions. So let me try to answer the easy ones. I'll start with the second question. The net investment income for the two things, which you just mentioned, are in assets mainly coming from the toothbrush investments which we made in 2017, if I remember correctly. And we still have a sizable stake left on this company. And then together with how this company is progressing, we'll try to dribble down our stake of this company. So I think you will still see some of that coming on to our way in the coming quarters. So then coming back to the guidance of Q3. The value, it may look a little bit low compared with same period last year. But I just mentioned in the prepared remarks that a lot of that is driven by the new product sales, which happened last year on the Xiaomi Band 5. And then this year, the new product introduction for Xiaomi is actually preponed by a quarter into Q2, right? And then on the other hand, our self-branded products are very much Q4 heavy this year versus last year, I think, we had a pace whereby there's a bit happened in Q3 and there were a bit happened in Q4. So yes, the first answer to that question is, it's very much driven by seasonality. The second reason, I think -- I also mentioned just now is the uncertainty on the COVID Delta variant, we cannot predict to what extent that's going to impact ourselves for the second half of this year. However, on a full-year basis, we're still expecting that on the full-year revenue year-on-year basis, we're still going to grow versus last year. I hope that answers the questions.

Yes. Okay. Very clear. Thank you, Leon.

The next question comes from Andre Lin with Citi. Please go ahead.

Hi. Thank you for taking my question. And I have a few questions regarding the non-GAAP adjustment. And I have noticed that there is RMB 24 million adjustment in a non-GAAP basis. And how should we estimate that number in the next few quarters to a net level be a recurring level going forward? And I also have a question regarding the third quarter breakdown. So given you have CNY 1.6 billion to CNY 1.8 billion revenue guidance, how should we think about the breakdown between self-branded product and some effect? Thank you.

Okay. Thank you. So, on the R&D adjustment, I think, you are referring to the share-based compensation amount, correct?

Yes.

Okay. Yes. So the share-based compensation amount actually happens on every single quarter. Some -- in certain quarters, it was a little bit lower; in certain quarters, it was a little bit higher. But I think on average, you can -- your model to plug in a number between 15 million to 20 million per quarter on the SBC expenses. But, however, as I said, I mean, because this is very much linked to the bonus cycle to the payment of the employees, so in certain quarters, probably we don't have any. And in certain quarters, we'll have a significant amount. That's why we're talking about the non-GAAP adjustments in our financials as well.

Okay. Thank you.

Does that your answer your? Okay. And then on the third quarter split between our self-branded and Xiaomi products, I think, what I can say at this moment is that our self-branded products will continue the growth rate, which we kind of see in the past quarters. I think from last year Q3, you saw the trend that our self-branded products start to accelerate. I think last year Q3, the base was around RMB 400 million to RMB 500 million, if I remember correctly by heart. In Q3, we will continue a high double-digit percentage growth of our self-branded products, right? So that speed and trend is continue to go on in the second half of this year. And on the other hand, the Xiaomi volume and revenue is still subject to certain market conditions. And also I have mentioned a few times that the fitness band product category is becoming a mature category. And also, if you look at the IDC report, the overall market size on the fitness band market also is showing a decline rather than an increase quarter-on-quarter. So there's going to be some limitations on how much we could grow on the Xiaomi Band revenue per se. But, however, we have the self-branded products which with the growth and that should provide a good cost coverage for our profitability going forward.

Thank you. Very clear. Thank you very much.

The next question comes from [Robert McKay with Blue Lotus] [ph]. Please go ahead.

Hi, there. Thanks for taking my questions. Just first of all congratulations on your smartwatch launch in the third quarter and also those innovations that you made with Zepp OS and your SoC Huangshan. And I also look forward to seeing what's happening in the fourth quarter. You mentioned that you have a lot of surprises coming in the fourth quarter. And so I actually really want to ask about that is right now you have a tie-up with Xiaomi on Mi Band. And I'm wondering if you have any other kind of tie-ups with Xiaomi on other types of products. Because as you mentioned, smart bands are declining. And so what we want to see is other tie-ups smartwatches, kids watches, is that something that might be possible, if not in fourth quarter, but in the future?

Yes. No, so thank you for the question I think it's a very good question. As we just mentioned in the prepared remarks we also mentioned that we have some exciting products with Xiaomi, which is being developed as we speak right? So -- and unfortunately these are under the confidentiality agreement so I cannot say too much about it. But I think we have a good strategic partnership with Xiaomi on the wearable market. So I have to ask you to just waiting to be surprised.

Okay. Thank you. I'm ready to be surprised. I do have some other questions if that's okay. So as you know Zepp kind of sees themselves like a health company. And so health isn't really limited to smart bands and smart watches. So we're wondering if there's any kind of other medical grade products that you might have in store and if so what the progress is like on that.

There are a few, right? So I think what Huang just mentioned in his script was that apart from the smartwatch and band products, we also have a very interesting line of TWS headphones. And it not only have the traditional noise canceling the mainstream functionalities people has, we also have the TWS headphones equipped with the PPG sensor which is to measure the heart rate from your headphones, right? So there are a few of these coming to the market or in the pipeline which are in the making. And regarding the medical devices, I think we also just mentioned in the July conference, the developer conference that we have the cutting-edge non-squeeze blood pressure measurement capability, which is going to be put into our next-generation watch later this year, right? So that is I mean a blood pressure functionality by definition that is a medical-grade product. And then similar to what Apple Watch is doing, we have to go through a medical certification on those things, if we have to sell, right? This is just one of the examples. And I think we have a few of that which is in the making and -- which is on the product pipeline for the future quarters.

Okay. Great. Thank you. Those are really great answers. Thank you. I do have one more question. Actually, in contrast to what Clive asked earlier, your third quarter guidance I thought was pretty strong considering you don't have any new product launches this quarter. And so I'm wondering where you're seeing that strength coming from is. I know you mentioned earlier that you're seeing a lot of growth from your self-branded products. So I was wondering what kind of growth -- or are we seeing -- what kind of growth are we seeing from your Xiaomi Mi Band in the third quarter?

Yeah. No, the Xiaomi Mi Band for third quarter probably is going to be in a decline. That's what -- if you do the math you probably can't do that because last year same period I mean, we have the Mi Band 5 launched and then this year it has been preponed to Q2, right? But then the decline will be to a big extent made up by our self-branded products growth, right? And then I have just answered Clive on his question, it's going to be a high double-digit growth for our self-branded products.

Okay. Okay. That makes sense. Okay. So you're saying high double-digit growth. Is that quarter-over-quarter or year-over-year?

That's quarter-over-quarter. Q3 versus last year Q3. Yeah.

Okay. Okay. So Q3 versus Q3 last year, it's going to be...

Yeah, that Q3 -- yeah that's Q3 2021 versus Q3 2020.

Okay. Great. And so…

But still, if you're talking about quarter-on-quarter growth there should be.

Okay. So because if you're saying that there's a quarter -- year-over-year double-digit, doesn't that mean by quarter-over-quarter maybe a slight decline?

Not necessarily.

No. Not necessarily. Okay.

Not necessarily.

Okay. Thank you.

Okay. Thank you very much.

[Operator Instructions] The next question comes from Marcel Münch with DONGXii. Please go ahead. Marcel Münch: Congrats, and thanks for taking my question. My question is regarding the news around the insurance business and partnering with Zurich Brazil and ERGO China Life. Can you share or maybe elaborate what will be the revenue of business model around this? And connected to that, what makes you confident that the data from the wearables is useful for those insurance companies that you're partnering up with? Thanks.

For this question, I will refer to Mike.

Yes. Hi. Thanks for the question. Yes, currently with Zurich Brazil and other big insurance companies we are going through their -- conducting pilots with them. And the big revenue will come after the pilots are finished. We have made -- Zurich and us for example, we have already made press releases about our corporation, about the pilot content. But the pilot is actually a great demonstration that the insurance companies view that our -- the data including the PAI health score can really help them with their business to, for example, helping to make health insurance pricing based on the real-time health behavior through data collected by wearables. So, the pilot will help us to gain more insight and more improvements that the insurance companies may need for us to help them implement after the pilot. So, the -- most of the -- again, the revenue impact would probably be after the pilots are finished. The pilots are ranged from six months to 12 months in duration. And we have multiple pilots with multiple insurance companies right now. Does that answer your question? Marcel Münch: Yes. More specifically I'm not so worried about like when will be the first revenues showing up, but rather like on the business model side like what's the idea behind it in terms of -- is there an idea to underwrite the business that insurance for instance together, or would even Zepp consider launching their own insurance and the insurance partner is kind of just partnering on that side, or is it for instance that Zepp Health is looking to kind of feed the data into the systems and thereby getting a revenue stream for the data? Is there any specifics on that that you can share at this point? Thanks.

Yes. So, we have different partnerships with different insurance companies. Some insurance companies look to use our data and our PAI health technology to do customer -- to do better customer acquisition and generate more customer engagement with the insurance companies' applications. Other pilots that we engage with they are using our data to try to do better underwriting and also set more appropriate health insurance pricing based on data that they gathered from our smart wearables. So, different insurance companies actually have different objectives for our PAI health data. We also, for example, engaging with some insurance companies to work on corporate wellness corporate wellness health. And that is also leveraging the PAI Health data to monitor the health of the employees. So, there are different engagement and objectives that we can accomplish with PAI Health for the insurance companies. Marcel Münch: Right. That's really interesting. And sorry my last question would be then--

Excuse me; allow me to add one more thing to it. I think as Mike just mentioned on the business model, it's almost everything which you just mentioned. There's one more thing we have is that we also have a brokerage license in China. And we also will not rule out the possibility that in the future we'll do the insurance program ourselves, right? But then I think the short answer to it is that different monetization ways we're exploring and we're -- according to the outcome of those different pilot programs we should be able to identify a key revenue stream coming out of the insurance program here. Marcel Münch: Thanks a lot. That's really insightful and great answers. My last question to that is like where would you see Zepp Health fitting in this new governmental regulations and strategies here? Also thinking about regulations around insurance or health data and so on.

Yes, that's a good question. So, first, it's not in my position to comment on the government policies and regulations. But as a company, there are a few things I could comment on. So, number one is we definitely position the security and privacy -- the customer user data security and privacy as the most important things in our day-to-day work, right? For example, we're in compliance with Europe GDPR, we're compliant in United States on HIPAA, and we do local data storage as well, right? So all those rules and regulations on data storage, we're compliant in almost every country we operate with. And this is also quite key in our management agenda. So that's number one. Number two I think, if you're looking at the Chinese regulation towards insurance, I think the government definitely wanted the technology to be part of the – let's say, the traditional insurance industry, right? So they are – basically, there are different rules and regulations, which has been published in the course of this year. For example, a traditional insurance company need and they can buy a so-called third-party service on telehealth or something like a PAI Health, this type of digital health product services to couple with the traditional insurance program, right? And we – given our unique expertise and what Mike explained here we think we're well positioned to capture this opportunity going forward. And I don't know whether or not you're referring to the latest regulation change in China on the online education business, or the e-commerce online entertainment business per sequential, but I think what draws us apart from those business is that, we are a maker of smart health devices, right, versus the other guys they're just doing e-commerce and online entertainment stuff, right? And I think the long-term goal of the Chinese government and also governments around the world is to tackle the global aging problem, to give more tools and equipment towards the consumer, which is affordable, so they can do self-quantification, and then to monitor their health. So our strategy to connect health with technology also position us towards that part of the vision like the governments of the global communities is going to do. So I think that's just a few census from our side.

Let me also just add quickly that at our board level, we do have a Board-level committee composed of independent Board directors. It's a big data and user privacy ethics committee. And this capitalize provides corporate governance for our companies, again, complying with all the different international user data privacy regulations, where we operate. So we have a very strong corporate governance, regarding user privacy as well as data security. Thank you. Marcel Münch: Thanks very much.

As there are no further questions now, I'd like to turn the call back over to the company for closing remarks.

Thank you, once again for joining us today. If you have further questions, please feel free to contact the Investor Relations department. This concludes this conference call. Thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.